1. Home
  2. CPAY vs BIIB Comparison

CPAY vs BIIB Comparison

Compare CPAY & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corpay Inc.

CPAY

Corpay Inc.

HOLD

Current Price

$299.20

Market Cap

22.5B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$171.90

Market Cap

27.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPAY
BIIB
Founded
1986
1978
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.5B
27.1B
IPO Year
2010
1996

Fundamental Metrics

Financial Performance
Metric
CPAY
BIIB
Price
$299.20
$171.90
Analyst Decision
Buy
Buy
Analyst Count
12
28
Target Price
$379.00
$197.46
AVG Volume (30 Days)
597.0K
882.8K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
7.59
N/A
EPS
15.03
8.79
Revenue
$4,528,403,000.00
$9,890,600,000.00
Revenue This Year
$18.83
N/A
Revenue Next Year
$10.56
N/A
P/E Ratio
$19.52
$20.18
Revenue Growth
13.93
2.22
52 Week Low
$252.84
$110.04
52 Week High
$361.99
$202.41

Technical Indicators

Market Signals
Indicator
CPAY
BIIB
Relative Strength Index (RSI) 46.46 36.88
Support Level $276.91 $170.99
Resistance Level $316.98 $184.16
Average True Range (ATR) 10.84 5.30
MACD 0.92 -1.15
Stochastic Oscillator 53.68 13.86

Price Performance

Historical Comparison
CPAY
BIIB

About CPAY Corpay Inc.

Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. The company offers payment and spend management solutions, including accounts payable automation, cross-border payments, commercial card programs, vehicle payment solutions, and lodging payment services. Its reportable segments are: Corporate Payments, Vehicle Payments, Lodging Payments and Other. The majority of the company's revenue is derived from the Vehicle Payments segment, which helps customers to pay for vehicle related expenses. Geographically, it derives the maximum revenue from the United States and the rest from Brazil, the United Kingdom and other countries.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: